Isradipine--a calcium channel blocker--does not potentiate chloroquine antiplasmodial activity against Plasmodium falciparum.
Culturing fresh clinical isolates of P. falciparum and using the isotopic method, we tested separately chloroquine and isradipine--a calcium channel blocker--, and also the combination isradipine plus chloroquine. Tested wild isolates were chloroquine-sensitive. With regard to the combination isradipine/chloroquine, the isobolograms obtained indicate that isradipine antagonises chloroquine antiplasmodial activity. Taking into account these findings, we discuss the issues related to the calcium channel blocker molecules.
Groupe de Recherche sur le Paludisme, Institut Pasteur de Madagascar, Antananarivo. milijaon@pasteur.mg
M
M
Randrianarivelojosia
R
R
Jambou
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002738:Chloroquine / Q000494:pharmacology*; D004351:Drug Resistance; D004357:Drug Synergism; D006801:Humans; D017275:Isradipine / Q000494:pharmacology*; D008270:Madagascar; D016778:Malaria, Falciparum / Q000188:drug therapy; D021261:Parasitic Sensitivity Tests; D010963:Plasmodium falciparum / Q000187:drug effects*
D000962:Antimalarials; D002121:Calcium Channel Blockers; D002738:Chloroquine; D017275:Isradipine